Madrigal Pharma (MDGL) Reports Prelim Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Salesforce president Srini Tallapragada steps down, becomes advisor
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
January 13, 2025 6:45 AM ESTPreliminary fourth-quarter and full-year 2024 Rezdiffra (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectivelyPreliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 millionAs of year-end 2024, more than 11,800 patients on RezdiffraMadrigal to present at the 43rd Annual J.P. Morgan Healthcare Conference at 2:15 p.m. PST (5:15 p.m. EST) on Wednesday January 15, 2025
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... More
